Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 14

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 14
---
 the event that we do not sell an amount of 
 securities sufficient to pursue the business goals outlined in this prospectus.          |

| ● | Purchasers                                                                                         
 of our securities in this offering pursuant to a securities purchase agreement may have additional 
 rights.                                                                                            |

| ● | There                                                                   
 is no public market for the April 2025 Warrants or Pre-Funded Warrants. |

| ● | The                                                             
 April 2025 Warrants in this offering are speculative in nature. |

| ● | Holders                                                                                        
 of warrants purchased in this offering will not have rights of holders of our shares of Common 
 Stock until exercised.                                                                         |

| ● | The                                                                                      
 April 2025 Warrants are not be exercisable until we obtain Warrant Stockholder Approval. |

| ● | If                                                                                         
 we do not maintain a prospectus relating to the Common Stock issuable upon exercise of the 
 April 2025 Warrants and Pre-Funded Warrants, public holders will only be able to exercise  
 on a “cashless basis.”                                                                     |

| ● | We                                                                                          
 may be required to repurchase the April 2025 Warrants.                                      |
| ● | If                                                                                          
 the April 2025 Warrants are exercised after a reverse stock split and/or the exercise price 
 is reset stockholders will suffer substantial dilution.                                     |

Risks Related to our Diagnostic Product

| ● | The                                                                                 
 FDA could impose greater regulatory burdens on laboratory developed tests (“LDTs”). |

| ● | Delays                                                                                     
 or difficulties in the enrollment of patients could delay or prevent regulatory approvals. |

| ● | Clinical                                                         
 trials are expensive, time-consuming, and may not be successful. |

Risks Related to Our Diagnostic Tests

| ● | If                                                                                         
 our tests do not perform as expected, our operating results, reputation, and business will 
 suffer.                                                                                    |

| ● | We                                                                                            
 may experience difficulties that delay or prevent our development, introduction, or marketing 
 of enhanced or new tests.                                                                     |

| ● | Clinical                                                                                          
 testing of a particular diagnostic test or therapeutic product candidate may not yield successful 
 results.                                                                                          |

| ● | Even                                                                                      
 if our diagnostic tests or therapeutic products receive marketing approval, we may not be 
 successful in commercializing them.                                                       |

| ● | We                                                                   
 are currently dependent upon PPLS to offer and perform CyPath® Lung. |

| ● | If                                                                                             
 we cannot convince physicians of the benefits of our diagnostic tests or therapeutic products,